281 related articles for article (PubMed ID: 17064205)
1. Role of P-glycoprotein in statin drug interactions.
Holtzman CW; Wiggins BS; Spinler SA
Pharmacotherapy; 2006 Nov; 26(11):1601-7. PubMed ID: 17064205
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
3. Statin safety and drug interactions: clinical implications.
Bottorff MB
Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
[TBL] [Abstract][Full Text] [Related]
4. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Shitara Y; Sugiyama Y
Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Neuvonen PJ; Niemi M; Backman JT
Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
[TBL] [Abstract][Full Text] [Related]
8. [Metabolic interactions with statins].
Molden E; Asberg A
Tidsskr Nor Laegeforen; 2001 Jan; 121(2):189-93. PubMed ID: 11475198
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
[TBL] [Abstract][Full Text] [Related]
10. Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats.
Dong J; Yu X; Wang L; Sun YB; Chen XJ; Wang GJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1247-52. PubMed ID: 18817631
[TBL] [Abstract][Full Text] [Related]
11. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
[TBL] [Abstract][Full Text] [Related]
13. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).
Marchetti S; Mazzanti R; Beijnen JH; Schellens JH
Oncologist; 2007 Aug; 12(8):927-41. PubMed ID: 17766652
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
15. Emerging significance of P-glycoprotein in understanding drug disposition and drug interactions in psychopharmacology.
Carson SW; Ousmanou AD; Hoyler SL
Psychopharmacol Bull; 2002; 36(1):67-81. PubMed ID: 12397848
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Schwab D; Fischer H; Tabatabaei A; Poli S; Huwyler J
J Med Chem; 2003 Apr; 46(9):1716-25. PubMed ID: 12699389
[TBL] [Abstract][Full Text] [Related]
17. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.
Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD
J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306
[TBL] [Abstract][Full Text] [Related]
19. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs.
Li J; Volpe DA; Wang Y; Zhang W; Bode C; Owen A; Hidalgo IJ
Drug Metab Dispos; 2011 Jul; 39(7):1196-202. PubMed ID: 21447733
[TBL] [Abstract][Full Text] [Related]
20. HMG-CoA reductase inhibitors and P-glycoprotein modulation.
Bogman K; Peyer AK; Török M; Küsters E; Drewe J
Br J Pharmacol; 2001 Mar; 132(6):1183-92. PubMed ID: 11250868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
